Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969782175> ?p ?o ?g. }
- W2969782175 endingPage "2617" @default.
- W2969782175 startingPage "2600" @default.
- W2969782175 abstract "Recently, immunotherapy has been shown to be an effective and helpful therapeutic option for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor T cells may be restored through the checkpoint blockade using anti-programmed death 1 or anti-programmed death ligand 1 (PD-L1) antibodies, showing, in several cancer patients, an increased progression-free survival and overall survival compared with classical chemotherapy. As recently shown by several studies, the PD-L1 expression levels in tumors may offer a selection criterion for patients to predict their immunotherapy response. In particular, NSCLC patients with high tumor PD-L1 levels (proportional score ≥ 50% for first-line therapy and ≥ 1% for second-line treatment, respectively) showed better response rates to immunotherapy and longer survival in first-line therapy compared with conventional chemotherapy. PD-L1, whose expression is evaluated by using immunohistochemistry analysis, is currently the only biomarker approved for clinical use in the first- and second-line monotherapy setting and therefore plays a central role in treatment decision-making for patients with advanced NSCLC. In this review we will discuss the key role of PD-L1 as a predictive biomarker of response to pembrolizumab therapy in NSCLC patients by describing the appropriate techniques and methodologies for immunohistochemical evaluation of PD-L1 expression and providing an overview of the clinical studies supporting its predictive significance." @default.
- W2969782175 created "2019-08-29" @default.
- W2969782175 creator A5002757210 @default.
- W2969782175 creator A5004847623 @default.
- W2969782175 creator A5011928740 @default.
- W2969782175 creator A5022206145 @default.
- W2969782175 creator A5033609878 @default.
- W2969782175 creator A5041428894 @default.
- W2969782175 creator A5056329331 @default.
- W2969782175 creator A5056636166 @default.
- W2969782175 creator A5058543770 @default.
- W2969782175 creator A5063239849 @default.
- W2969782175 creator A5072264918 @default.
- W2969782175 creator A5084174977 @default.
- W2969782175 date "2019-08-20" @default.
- W2969782175 modified "2023-10-08" @default.
- W2969782175 title "Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)" @default.
- W2969782175 cites W1577952101 @default.
- W2969782175 cites W1580205301 @default.
- W2969782175 cites W1645691607 @default.
- W2969782175 cites W1752668680 @default.
- W2969782175 cites W1781719481 @default.
- W2969782175 cites W1913780655 @default.
- W2969782175 cites W1956163040 @default.
- W2969782175 cites W1971988389 @default.
- W2969782175 cites W1975368779 @default.
- W2969782175 cites W1982488143 @default.
- W2969782175 cites W1982889687 @default.
- W2969782175 cites W2017712207 @default.
- W2969782175 cites W2030612376 @default.
- W2969782175 cites W2031373281 @default.
- W2969782175 cites W2039395562 @default.
- W2969782175 cites W2057499380 @default.
- W2969782175 cites W2092921437 @default.
- W2969782175 cites W2112121482 @default.
- W2969782175 cites W2118613671 @default.
- W2969782175 cites W2123010659 @default.
- W2969782175 cites W2128035403 @default.
- W2969782175 cites W2130473166 @default.
- W2969782175 cites W2136859769 @default.
- W2969782175 cites W2140875987 @default.
- W2969782175 cites W2166662937 @default.
- W2969782175 cites W2181211402 @default.
- W2969782175 cites W2182399485 @default.
- W2969782175 cites W2198093519 @default.
- W2969782175 cites W2236653151 @default.
- W2969782175 cites W2257916459 @default.
- W2969782175 cites W2260197997 @default.
- W2969782175 cites W2263759961 @default.
- W2969782175 cites W2281321365 @default.
- W2969782175 cites W2291219408 @default.
- W2969782175 cites W2339631364 @default.
- W2969782175 cites W2401835169 @default.
- W2969782175 cites W2467854262 @default.
- W2969782175 cites W2481433613 @default.
- W2969782175 cites W2507654187 @default.
- W2969782175 cites W2511043440 @default.
- W2969782175 cites W2512136042 @default.
- W2969782175 cites W2514478103 @default.
- W2969782175 cites W2516096091 @default.
- W2969782175 cites W2527905628 @default.
- W2969782175 cites W2531247827 @default.
- W2969782175 cites W2542773270 @default.
- W2969782175 cites W2557730509 @default.
- W2969782175 cites W2560367415 @default.
- W2969782175 cites W2572174216 @default.
- W2969782175 cites W2587327379 @default.
- W2969782175 cites W2590359520 @default.
- W2969782175 cites W2616943335 @default.
- W2969782175 cites W2655262992 @default.
- W2969782175 cites W2738311526 @default.
- W2969782175 cites W2753432434 @default.
- W2969782175 cites W2754223242 @default.
- W2969782175 cites W2757427979 @default.
- W2969782175 cites W2764262392 @default.
- W2969782175 cites W2765696340 @default.
- W2969782175 cites W2766342472 @default.
- W2969782175 cites W2786665544 @default.
- W2969782175 cites W2792508506 @default.
- W2969782175 cites W2792656817 @default.
- W2969782175 cites W2796582438 @default.
- W2969782175 cites W2797744035 @default.
- W2969782175 cites W2804957255 @default.
- W2969782175 cites W2809503383 @default.
- W2969782175 cites W2884883038 @default.
- W2969782175 cites W2886527406 @default.
- W2969782175 cites W2888059202 @default.
- W2969782175 cites W2892640821 @default.
- W2969782175 cites W2898176688 @default.
- W2969782175 cites W2901789539 @default.
- W2969782175 cites W2907440899 @default.
- W2969782175 cites W2908928362 @default.
- W2969782175 cites W2910245285 @default.
- W2969782175 cites W2912986834 @default.
- W2969782175 cites W2925446385 @default.
- W2969782175 doi "https://doi.org/10.1007/s12325-019-01057-7" @default.
- W2969782175 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6822831" @default.
- W2969782175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31432460" @default.